Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Brown University
Taurolidine has differing effects on adherent and floating melanoma cells
July 30th, 2003
Taurolidine has differing effects on adherent and floating melanoma cells. "The annual incidence of malignant melanoma is estimated at 10-12 per 100,000 inhabitants in countries of Central Europe and the U.S., with more recent estimates showing a dramatic upward trend," scientists in the United States report. "Taurolidine (Carter/Wallace, Cranberry, NJ) is a novel, potentially effective, antitumor chemotherapeutic agent. We hypothesized that Taurolidine could inhibit the growth, induce apoptosis, affect the cell cycle and change morphology of melanoma cells," wrote D.P. Shrayer and colleagues, Brown University. "We expected this...
Source: Biotech Week (2003-07-30)
|
